Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Doxorubicin pathways: pharmacodynamics and adverse effects.

Pharmacogenetics and genomics - 1 Jul 2011

Thorn Caroline F, Oshiro Connie, Marsh Sharon, Hernandez-Boussard Tina, McLeod Howard, Klein Teri E, Altman Russ B

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Doxorubicin
Share to Drug Resistance, Neoplasm
Share to Pharmacogenetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 21048526
DOI: 10.1097/FPC.0b013e32833ffb56
PMCID: PMC3116111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Doxorubicin pathways: pharmacodynamics and adverse effects.PMID 21048526Read ↗

New insights into the activities and toxicities of the old anticancer drug doxorubicinSemantic proximity Read ↗

Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic viewSemantic proximity Read ↗

Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profilingSemantic proximity Read ↗

Doxorubicin-Induced Cardiotoxicity in Breast Cancer: Mechanistic Pathways, Pharmacogenomic Modifiers, and Translational Strategies.Semantic proximity Read ↗

Drug pipeline: 1Q12.Semantic proximity Read ↗

Molecular avenues in targeted doxorubicin cancer therapySemantic proximity Read ↗

[Individualized drug therapy].Semantic proximity Read ↗

Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localizationSemantic proximity Read ↗

PARP inhibitors: the story is still unfolding.Semantic proximity Read ↗

Doxorubicin cardiotoxicity and target cells: a broader perspectiveSemantic proximity Read ↗

Mitochondrial signaling pathways and their role in cancer drug resistanceSemantic proximity Read ↗

Review on the Role of Epigenetic Modifications in Doxorubicin-Induced CardiotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.